BidaskClub downgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a buy rating to a hold rating in a report issued on Saturday, March 17th.
A number of other equities analysts have also recently commented on PIRS. ValuEngine cut Pieris Pharmaceuticals from a hold rating to a sell rating in a report on Friday, December 1st. HC Wainwright set a $9.00 price objective on Pieris Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, December 20th. Finally, William Blair assumed coverage on Pieris Pharmaceuticals in a report on Wednesday, January 17th. They set an outperform rating for the company. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Pieris Pharmaceuticals currently has a consensus rating of Buy and an average target price of $11.00.
Pieris Pharmaceuticals stock traded down $0.23 during mid-day trading on Friday, hitting $6.33. 341,765 shares of the company’s stock were exchanged, compared to its average volume of 871,110. Pieris Pharmaceuticals has a fifty-two week low of $2.26 and a fifty-two week high of $9.75. The company has a market capitalization of $340.90, a PE ratio of -15.83 and a beta of 1.71.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Friday, March 9th. The biotechnology company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.21. Pieris Pharmaceuticals had a negative return on equity of 162.54% and a negative net margin of 69.82%. The company had revenue of $18.15 million during the quarter, compared to analysts’ expectations of $7.63 million. equities research analysts predict that Pieris Pharmaceuticals will post -0.53 EPS for the current fiscal year.
In other news, major shareholder Orbimed Advisors Llc sold 7,897 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $8.98, for a total value of $70,915.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.05% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership acquired a new position in Pieris Pharmaceuticals during the fourth quarter valued at approximately $3,370,000. Teachers Advisors LLC acquired a new position in shares of Pieris Pharmaceuticals during the second quarter worth $308,000. JPMorgan Chase & Co. acquired a new position in shares of Pieris Pharmaceuticals during the third quarter worth $600,000. Creative Planning increased its holdings in shares of Pieris Pharmaceuticals by 18.2% during the fourth quarter. Creative Planning now owns 78,025 shares of the biotechnology company’s stock worth $589,000 after buying an additional 12,000 shares in the last quarter. Finally, Baird Financial Group Inc. acquired a new position in shares of Pieris Pharmaceuticals during the fourth quarter worth $477,000. Institutional investors and hedge funds own 43.99% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Lowers Pieris Pharmaceuticals (NASDAQ:PIRS) to Hold” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/bidaskclub-downgrades-pieris-pharmaceuticals-pirs-to-hold.html.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.